SEC ownership of Helus Pharma Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001833141.

Comparable stake leader

Venrock Healthcare Capital Partners III, L.P.

Disclosed value leader

Adage Capital Management, L.P.

Comparable rows

9/50

Latest evidence

13 Oct 2026

Top shareholders Insider holders Latest transactions

Public ticker: HELP on Nasdaq
Parsed ownership sources: 13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Venrock Healthcare Capital Partners III, L.P.
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 9 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Venrock Healthcare Capital Partners III, L.P.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 13 Oct 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001833141
Issuer location: Toronto

Ownership snapshot

Top shareholders of Helus Pharma Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Venrock Healthcare Capita...

Disclosed value leader

Adage Capital Management,...

Comparable rows

9/50

Latest evidence

13 Oct 2026

13D/G 3/4/5 13F Lead comparable stake: 9.9% 41 rows are not safely comparable across share classes. 13D/G row: Venrock Healthcare Capital Partners III, L.P. Showing 1-8 of 50 holder rows.

Quick read

Venrock Healthcare Capital Partners III, L.P. leads the comparable SEC ownership view at 9.9%.

9 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Venrock Healthcare Capital Partners III, L.P.'s linked filing trail.

Comparable ownership Top 5

Venrock Healthcare Capital Partne... 9.9%

Adage Capital Management, L.P. 7.5%

Eric H. L. So 5.8%

Paul Glavine 5.8%

ORBIMED ADVISORS LLC 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Venrock Healthcare Capital Partners III, L.P.	13D/G 13D/G	9.9% Reported 13D/G · 31 Oct 2025	$30,106,217 5,111,412 shares	$0	31 Oct 2025
Adage Capital Management, L.P.	13D/G 13D/G	7.5% Reported 13D/G · 30 Sep 2026	$57,532,125 5,479,250 shares	$0	30 Sep 2026
Eric H. L. So	13D/G 3/4/5 So Eric H. L. · Director 13D/G 3/4/5	5.8% Reported 13D/G · 01 Sep 2026	$50,653,586 4,423,894 shares	$0	01 Sep 2026
Paul Glavine	13D/G 3/4/5 Glavine Paul · Chief Growth Officer, Director 13D/G 3/4/5	5.8% Reported 13D/G · 01 Sep 2026	$50,465,371 4,407,456 shares	$0	01 Sep 2026
ORBIMED ADVISORS LLC	13D/G ORBIMED CAPITAL LLC 13D/G	4.9% Reported 13D/G · 31 Dec 2025	— 2,422,600 shares	$0	31 Dec 2025
Sirenia Capital Management LP	13D/G 13D/G	4.8% Reported 13D/G · 30 Jun 2026	$20,085,585 3,029,500 shares	$0	30 Jun 2026
Deep Track Capital, LP	13D/G 13D/G	4.7% Reported 13D/G · 31 Dec 2025	$18,486,334 2,391,505 shares	-$5,262,159	31 Dec 2025
MILLENNIUM MANAGEMENT LLC	13D/G 13D/G	1.4% Reported 13D/G · 30 Sep 2026	$10,699,206 1,018,972 shares	$0	30 Sep 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$9,670,162.

Buys

$9,670,162

Insiders: 4

Sells

Insiders: 0

Net

+$9,670,162

Shares: +788,000

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 788,000 Shares: 0

Window (months)	Buy shares	Buy value	Sell value	Net value
0-3	788,000	$9,670,162	$0	+$9,670,162
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-11 of 11 reporting-owner rows connected to Helus Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Paul Glavine

Net 12M change

+$9.67M

Full value: +$9,670,162 · USD · 12-month change

Latest report

16 Oct 2026

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Paul Glavine	Chief Growth Officer, Director	$32,925,282	+$4,715,337	+17%	Mixed	30 Sep 2026
Eric H. L. So	Director	$31,507,423	+$3,569,045	+13%	Mixed	30 Sep 2026
Amir Inamdar	Director	$2,799,932			Median	13 Oct 2026
Michael Halstead	Chief Executive Officer	$2,270,695	+$1,347,050	+146%	Filing P/S	21 Sep 2026
Grant Froese	Director	$1,981,922			Median	13 Oct 2026
Mark Lawson	Director	$1,966,719			Median	13 Oct 2026
Eric Hoskins	Director	$1,949,586			Median	13 Oct 2026
Freda Lewis-Hall	Director	$1,229,000			Median	13 Oct 2026
Theresa Firestone	Director	$944,842			Median	13 Oct 2026
Greg Cavers	Chief Financial Officer	$871,173	+$38,730	+4.7%	Mixed	29 Sep 2026
Suresh K. Durgam	Director				Mixed	16 Oct 2026

Recent insider transactions for Helus Pharma Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Eric H. L. So	HELP	Common Shares	Award	5.55%			248,000	4,713,014	30 Sep 2026	Direct
Paul Glavine	HELP	Common Shares	Award	5.51%			248,000	4,750,191	30 Sep 2026	Direct
Greg Cavers	HELP	Common Shares	Purchase		$38,730	$12.91	3,000	3,000	29 Sep 2026	Held by spouse
Michael Halstead	HELP	Common Shares	Purchase	145.8%	$1,347,050	$13.47	100,000	168,568	21 Sep 2026	Direct
Paul Glavine	HELP	Common Shares	Purchase	2.4%	$1,247,190	$12.47	100,000	4,271,252	08 Sep 2026	Direct
Paul Glavine	HELP	Common Shares	Purchase	2.4%	$1,247,190	$12.47	100,000	4,271,252	08 Sep 2026	Direct
Eric H. L. So	HELP	Common Shares	Purchase	2.29%	$1,238,670	$12.39	100,000	4,465,014	08 Sep 2026	Direct
Eric H. L. So	HELP	Common Shares	Purchase	2.34%	$1,208,900	$12.09	100,000	4,365,014	04 Sep 2026	Direct
Paul Glavine	HELP	Common Shares	Purchase	2.46%	$1,178,280	$11.78	100,000	4,171,252	03 Sep 2026	Direct
Eric H. L. So	HELP	Common Shares	Purchase	2.28%	$1,121,475	$11.80	95,000	4,265,014	01 Sep 2026	Direct
Paul Glavine	HELP	Common Shares	Purchase	2.26%	$1,042,677	$11.59	90,000	4,071,252	31 Aug 2026	Direct

^* marks a reported price that did not pass the local price check.